Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Shares Repurchased (2019 - 2025)

C4 Therapeutics' Shares Repurchased history spans 5 years, with the latest figure at $14000.0 for Q4 2025.

  • For Q4 2025, Shares Repurchased changed N/A year-over-year to $14000.0; the TTM value through Dec 2025 reached $193000.0, down 0.52%, while the annual FY2025 figure was $193000.0, 0.52% down from the prior year.
  • Shares Repurchased reached $14000.0 in Q4 2025 per CCCC's latest filing, down from $24000.0 in the prior quarter.
  • In the past five years, Shares Repurchased ranged from a high of $155000.0 in Q1 2025 to a low of $14000.0 in Q4 2025.
  • Average Shares Repurchased over 3 years is $71000.0, with a median of $85000.0 recorded in 2024.
  • Peak YoY movement for Shares Repurchased: skyrocketed 431.25% in 2024, then crashed 71.76% in 2025.
  • A 3-year view of Shares Repurchased shows it stood at $16000.0 in 2023, then surged by 431.25% to $85000.0 in 2024, then tumbled by 83.53% to $14000.0 in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Shares Repurchased are $14000.0 (Q4 2025), $24000.0 (Q3 2025), and $155000.0 (Q1 2025).